PATIENT INFORMATION SHEET

MOLNUPIRAVIR

What is COVID-19?

COVID-19 is an infectious disease caused by coronavirus, which can be transmitted via close contact with another infected person. COVID-19 illnesses can be very mild to severe, and may lead to deaths. Despite current evidence shows that most COVID-19 cases are mild, serious illnesses may develop and potentially worsen your medical conditions. The risk of hospitalization due to COVID-19 in elderly and all age groups with severe chronic medical conditions including cardiovascular disease, pulmonary disease and diabetes mellitus is higher.

What is Molnupiravir?

Molnupiravir is a medication under investigation and has been approved by the FDA for emergency use in adult patients with mild-to-moderate COVID-19 and at high risk for progression to severe COVID-19, including hospitalization or death, as well as for whom other COVID-19 treatment options are not clinically appropriate.

Molnupiravir is not authorized:

- For use in patients under 18 years old
- For COVID-19 prevention
- For patients requiring hospitalization due to COVID-19
- For use more than 5 consecutive days

Before taking Molnupiravir, what should I tell my healthcare professionals?

Please inform your healthcare professionals if you:

- Have any allergies
- Have liver or kidney disease
- Are pregnant / plan to become pregnant
- Are breastfeeding / plan to breastfeed
- Have any serious illnesses
- Are taking any medications (including prescription and over-the-counter medications, vitamins, and herbal supplements)

How should I take Molnupiravir?

- Follow the instructions from your healthcare professionals for taking Molnupiravir.
- Take 4 capsules of Molnupiravir twice a day every 12 hours (i.e. 8am and 8pm).
- Continuously take Molnupiravir for 5 days. Even if you feel better, do NOT stop taking the medication.

- Take Molnupiravir with or without food.
- Swallow the capsules whole. Do NOT chew, break or crush the capsules. If you have any swallowing difficulty, let your healthcare professionals know.
- If you miss a dose:
 - If you miss a dose within 10 hours from the scheduled time, take Molnupiravir immediately.
 - o If you miss a dose more than 10 hours from the scheduled time, skip the missed dose and take the next dose at the next scheduled time. Do NOT double the dose.

What are the possible side effects of Molnupiravir?

- Hypersensitivity reactions
 - Allergic reactions may arise even with only one dose of Molnupiravir. If the following symptoms appear, stop taking Molnupiravir and inform your healthcare professionals right away:
 - Urticaria or skin rash
 - Increase in heart rate
 - Swallowing or breathing difficulties
 - Swelling of the mouth, lips or face
 - Throat tightness
 - Hoarseness of voice

Other common side effects include:

- Diarrhoea
- Nausea
- Dizziness

These are not all the possible side effects of Molnupiravir. Not many people have taken Molnupiravir and there are chances that other serious and unexpected side effects may happen. Molnupiravir is still being studied so not all risks are known yet.

Potential serious side effects:

Molnupiravir may cause harm to unborn babies. It is currently not known if taking Molnupiravir during pregnancy would pose harm to your baby.

- Molnupiravir is not recommended for use in pregnancy.
- There are currently no human studies of using Molnupiravir in pregnancy. Based on animal reproduction studies, Molnupiravir may lead to fetal harm.
- Discuss with your healthcare professionals about the benefits and risks of taking Molnupiravir during pregnancy.

For individuals who are planning to become pregnant:

- When taking Molnupiravir and for 4 days after the last dose of Molnupiravir, use effective contraceptive measures. Consult your healthcare professionals for reliable birth control methods
- Before starting Molnupiravir, you may be required to test for pregnancy.
- Inform your healthcare professionals immediately if you become pregnant or think you may be pregnant during your treatment.

For individuals who are sexually active with partners who are able to become pregnant:

It is not known if Molnupiravir can affect sperm. Although the risk is regarded as low, animal studies to fully evaluate the potential impact on the babies of males treated with Molnupiravir have not been completed. When taking Molnupiravir and for at least 3 months after the last dose of Molnupiravir, use correct and reliable contraceptive measures consistently. The risks to sperm beyond 3 months after treatment remains unknown and are still under ongoing assessment. If you have any concerns, ask your healthcare professionals.

What if I am breastfeeding?

Breastfeeding is not recommended during Molnupiravir treatment and for 4 days after the last dose of Molnupiravir. If you are breastfeeding or plan to breastfeed, discuss your specific situation and options with your healthcare professionals.

What are my other treatment options?

There are other possible approved therapies for treating COVID-19. If you need more information about your treatment options, please consult your healthcare professionals. Taking Molnupiravir or not is your personal choice. Your standard treatment will not be affected if you decide not to take Molnupiravir.

How should I report side effects associated with Molnupiravir?

Contact your healthcare professionals if you have any side effects that bother you or do not go away.

How should I store Molnupiravir?

- Store Molnupiravir capsules at room temperature between 20°C to 25°C.
- Keep Molnupiravir and all medications out of the reach of children and pets.

Reference: Fact Sheet For Patients And Caregivers – Emergency Use Authorization (EUA) Of Molnupiravir For Coronavirus Disease 2019 (COVID-19)

Prepared by Pharmacy Department, Gleneagles Hospital Hong Kong

Version 1 May 2022